SCOPUS 정보 검색 플랫폼

Japanese Journal of Clinical Oncology

Volumn 31, Issue 2, 2001, Pages 69-73

Altretamine is an effective palliative therapy of patients with recurrent epithelial ovarian cancer

(1) Malik, Imtiaz A a,b

a National Cancer Institute (Pakistan)

b UNIVERSITY OF CINCINNATI (United States)

Author keywords

Altretamine; Epithelial ovarian cancer; Recurrent disease

Indexed keywords

ALTRETAMINE; CYTOTOXIC AGENT; PLATINUM;

ARTICLE; ASTHENIA; BONE MARROW; CANCER CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; HUMAN; KIDNEY FUNCTION; LIVER FUNCTION; NAUSEA AND VOMITING; OVARY ADENOCARCINOMA; OVARY CANCER; PROSPECTIVE STUDY; SHORT COURSE THERAPY;

EID: 0035072411 PISSN: 03682811 EISSN: None Source Type: Journal
DOI: 10.1093/jjco/hye012 Document Type: Article

Times cited : (15)

References (34)

1
- 0001802909
- Cancer of the ovary
- In: DeVita VT Jr, Hellman SA, editors; Philadelphia, PA: Lippincott
- (1993) Cancer: Principles and Practice of Oncology, 4th ed , pp. 1126-1263
- Young, R.C.¹ Perez, C.A.² Hoskins, W.J.³

2
- 0027512483
- The addition of etoposide and ifosfamide to cisplatin as second-line therapy in ovarian carcinoma
- (1993) Eur J Gynecol Oncol , vol.14 , pp. 18-22
- Baker, T.R.¹ Piver, M.S.² Hempling, R.E.³

3
- 0028088853
- Oral etoposide is active against platinum-resistant epithelial ovarian cancer
- (1994) J Clin Oncol , vol.12 , pp. 60-63
- Hoskins, P.¹ Swenerton, K.D.²

4
- 0027055485
- Phase II study and long term follow-up of patients treated with Taxol for advanced ovarian cancer adenocarcinoma
- (1992) J Clin Oncol , vol.10 , pp. 1748-1753
- Einzig, A.I.¹ Wiernik, P.H.² Sasloff, J.³ Runowicz, C.D.⁴ Goldberg, G.L.⁵

5
- 0028153230
- Phase II trial in patients with progressive ovarian carcinoma after platinum-based chemotherapy: A Gynecological Oncology Group Study
- (1994) J Clin Oncol , vol.12 , pp. 1748-1753
- Thigpen, J.T.¹ Blessing, J.A.² Ball, H.³ Hummel, S.J.⁴ Barrett, R.J.⁵

6
- 0027999966
- European-Canadian randomized trail of paclitaxel in relapsed ovarian cancer: High dose versus low-dose and long versus short infusion
- (1994) J Clin Oncol , vol.12 , pp. 2654-2666
- Eisenhauer, E.A.¹ Ten Bokkel Huinink, W.W.² Swenerton, K.D.³ Gianni, L.⁴ Myles, J.⁵ Van Der Burg, M.E.⁶

7
- 0031239998
- Topotecan in platinum- and paclitaxel-resistant ovarian cancer
- (1997) Gynecol Oncol , vol.66 , pp. 480-486
- Swisher, E.M.¹ Mutch, D.G.² Rader, J.S.³ Elbendary, A.⁴ Herzog, T.J.⁵

8
- 0030900145
- Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer
- (1997) J Clin Oncol , vol.15 , pp. 2183-2193
- Ten Bokkel Huinink, W.¹ Gore, M.² Carmicheal, J.³ Gordon, A.⁴ Malfetano, J.⁵ Hudson, I.⁶

9
- 0026517086
- Responses to salvage chemotherapy in ovarian cancer: A critical need for precise definitions of the treated population
- (1992) J Clin Oncol , vol.10 , pp. 513-514
- Markman, M.¹ Hoskins, W.²

10
- 0025849666
- Hexamethylmelamine (altretamine) activity as a single agent in previously untreated advanced ovarian cancer
- (1991) Cancer Treat Rev , vol.18 , Issue.SUPPL. A , pp. 15-21
- Wharton, J.T.¹

11
- 0025726127
- Hexamethylmelamine (altretamine): Early National Cancer Institute trials
- (1991) Cancer Treat Rev , vol.18 , Issue.SUPPL. A , pp. 31-35
- Young, R.C.¹

12
- 0025825508
- Randomized comparison of hexamethylmelamine, adriamcyin; cyclophosphamide (HAC) vs. cisplatin, adriamycin, cyclophosphamide (PAC) in advanced ovarian cancer: Long-term results
- (1991) Cancer Treat Rev , vol.18 , Issue.SUPPL. A , pp. 37-46
- Sessa, C.¹ Colombo, N.² Bolis, G.³ Marsoni, S.⁴ Mangioni, C.⁵

13
- 0025872290
- A comparison of hexamethylmelamine (altretamine), cyclophosphamide, doxorubicin and cisplatin (H-CAP) vs. cyclophosphamide vs. cyclophosphamide, doxorubicin and cisplatin (CAP) in advanced ovarian cancer
- (1991) Cancer Treat Rev , vol.18 , Issue.SUPPL. A , pp. 47-55
- Greco, F.A.¹ Johnson, D.² Hainsworth, J.D.³

14
- 0018872138
- Treatment of advanced ovarian carcinoma with a combination of hexamethylmelamine, cyclophosphamide, methotrexate and 5-fluorouracil (Hexa-CAF) in patients with and without previous treatment
- (1980) Cancer Treat Rep , vol.64 , pp. 323-326
- Neijt, J.P.¹ Van Lindert, A.C.M.² Vendrik, C.P.J.³ Roozendaal, K.J.⁴ Stuyvenberg, A.⁵ Pinedo, H.M.⁶

15
- 0025753293
- Hexamethylmelamine for the treatment of ovarian cancer - The Mount Sinai experience
- (1991) Cancer Treat Rev , vol.18 , Issue.SUPPL. A , pp. 57-65
- Bruckner, H.W.¹ Cohen, C.² Mandeli, J.³ Chesser, M.R.⁴ Kabakow, B.⁵ Wallach, R.⁶

16
- 0028825802
- A phase II study of carboplatin and hexamethylmelamine as induction chemotherapy in advanced epithelial ovarian carcinoma
- (1995) Eur J Cancer , vol.31 A , pp. 1778-1780
- Kristensen, G.B.¹ Baekelandt, M.² Vergote, I.B.³ Trope, C.⁴

17
- 58149211987
- Carboplatin (CBDCA) - Hexamethylmelamine (HMM) - Oral etoposide (VP-16) first-line treatment of ovarian cancer patients with bulky disease: A phase II study
- (1995) Gynecol Oncol , vol.58 , pp. 68-73
- Frasci, G.¹ Comella, G.² Comella, P.³ Conforti, S.⁴ Mastrantinio, P.⁵ Zullo, F.⁶

18
- 0018230635
- Hexamethylmelamine in alkylating agent-resistant ovarian carcinoma
- (1978) Cancer , vol.42 , pp. 2157-2161
- Johnson, B.L.¹ Fisher, R.I.² Bender, R.A.³ De Vita V.T., Jr.⁴ Chabner, B.A.⁵ Young, R.C.⁶

19
- 0019445150
- Hexamethylmelamine in mustard-resistant ovarian adenocarcinoma
- (1981) Cancer Treat Rep , vol.65 , pp. 530-531
- Omura, G.A.¹

20
- 0018755309
- Phase II trial of hexamethylmelamine in ovarian carcinoma resistant to alkylating agents
- (1979) Cancer Treat Rep , vol.63 , pp. 137-138
- Bonomi, P.D.¹ Mladineo, J.² Morrin, B.³ Wilbanks G., Jr.⁴ Slayton, R.E.⁵

21
- 0019155718
- Combination chemotherapy of advanced ovarian cancer with hexamethylmelamine, cis-platinum and doxorubicin after failure of prior therapy
- (1980) Obstet Gynecol , vol.56 , pp. 635-640
- Yogl, S.E.¹ Pagano, M.² Kaplan, B.H.³ Einhorn, N.⁴ Arseneau, J.⁵ Moukhtar, M.⁶

22
- 0020423597
- Hexamethylmelamine and melphalan as salvage therapy in advanced ovarian carcinoma
- (1982) J Surg Oncol , vol.21 , pp. 159-161
- Tempero, M.A.¹ Kessinger, A.²

23
- 0025818022
- Hexamethylmelamine chemotherapy for resistant or recurrent epithelial ovarian cancer
- (1991) Am J Obstet Gynecol , vol.165 , pp. 573-576
- Moore, D.H.¹ Fowler, W.C.² Jones, C.P.³ Crumpler, L.S.⁴

24
- 0000716409
- Oral hexamethylmelamine: An effective salvage therapy for recurrent ovarian cancer
- Abstract 2048
- (1991) Int J Gynecol Obstet , pp. 515
- Fields, A.L.¹ Schink, J.C.² Miller, D.S.³ Rademaker, A.W.⁴ Lurain, J.R.⁵

25
- 0027066977
- Hexamethylmelamine as second-line therapy in platinum-resistant ovarian cancer
- (1992) Gynecol Oncol , vol.47 , pp. 282-286
- Vergote, I.¹ Himmelmann, A.² Frankendal, B.³ Scheistrøen, M.⁴ Vlachos, K.⁵ Tropé, C.⁶

26
- 0031193915
- Hexamethylmelamine as a single second-line agent in ovarian cancer: Follow-up report and review of the literature
- (1997) Gynecol Oncol , vol.66 , pp. 20-25
- Manetta, A.¹ Tewari, K.² Podczaski, E.S.³

27
- 0000626028
- Altretamine (Hexalen): An effective salvage chemotherapy after paclitaxel (Taxol) in women with recurrent platinum resistant ovarian cancer
- (1995) Proc Am Soc Clin Oncol , vol.14 , pp. 275
- Schink, J.¹ Harris, L.² Grosen, E.R.³ Balley, H.H.⁴

28
- 0032103330
- Altretamine (hexamethylmelamine) in platinum-resistant and platinum-refractory ovarian cancer: A Gynecological Oncology Group phase II trial
- (1998) Gynecol Oncol , vol.69 , pp. 226-229
- Markman, M.¹ Blessing, J.A.² Moore, D.³ Ball, H.⁴ Lentz, S.S.⁵

29
- 0032063111
- Pattern of malignant tumors observed in a university hospital: A retrospective analysis
- (1998) J Pak Med Assoc , vol.48 , pp. 120-122
- Malik, I.¹ Khan, W.A.² Khan, Z.K.³

30
- 0031028270
- Phase II trial of oral altretamine for relapsed ovarian carcinoma: Evaluation of defining response by serum CA-125
- (1997) J Clin Oncol , vol.15 , pp. 172-176
- Rustin, G.J.S.¹ Nelstrop, A.E.² Crawford, M.³ Ledermann, J.⁴ Lambert, H.E.⁵ Coleman, R.⁶

31
- 0003506758
- Bethesda, MD: Division of Cancer Treatment, National Cancer Institute
- (1988) Guideliens for Reporting of Adverse Drug Reactions

32
- 0003486933
- Geneva: World Health Organization
- (1979) Handbook for Reporting Results of Cancer Treatment. WHO Publication No. 48

33
- 0027087463
- Phase II trial of intravenous hexamethylmelamine in patients with advanced ovarian cancer
- (1992) Invest New Drugs , vol.10 , pp. 229-301
- Hauge, M.D.¹ Long, H.J.² Hartmann, L.C.³ Edmonson, J.H.⁴ Webb, M.J.⁵ Su, J.⁶

34
- 0031055830
- Phase II study of liposomal doxorubicin in refractory ovarian cancer: Antitumor activity and toxicity modification by liposomal encapsulation
- (1997) J Clin Oncol , vol.15 , pp. 987-993
- Muggia, F.M.¹ Hainsworth, J.D.² Jeffers, S.³ Miller, P.⁴ Groshen, S.⁵ Tan, M.⁶

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.